Welcome to our dedicated page for Indivior Pharmaceuticals SEC filings (Ticker: INDV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Indivior PLC (NASDAQ: INDV) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a pharmaceutical issuer focused on opioid use disorder (OUD) treatments, Indivior uses its filings to report financial results, strategic initiatives, governance changes, and key legal and regulatory matters.
Investors can review Form 8-K current reports in which Indivior details material events such as quarterly financial results, updates on the Indivior Action Agenda, restructuring charges, optimization of its Rest of World business, and changes to executive compensation or board composition. Other 8-K items describe the company’s intent to redomicile from the U.K. to Delaware, shareholder approvals of a scheme of arrangement and amended articles of association, and the conclusion of a legacy U.S. Department of Justice resolution agreement.
Through its periodic reports (Forms 10-K and 10-Q, when available on EDGAR), readers can examine segment performance, revenue composition, R&D spending, and risk factors related to Indivior’s OUD-focused portfolio, including SUBLOCADE, SUBOXONE Film, PERSERIS, and OPVEE. These filings also typically include detailed discussions of non-GAAP measures such as adjusted EBITDA and non-GAAP operating expenses, along with reconciliations to U.S. GAAP metrics.
Stock Titan enhances these documents with AI-powered summaries that highlight the most important points in lengthy filings, helping users quickly understand changes in guidance, restructuring actions, legal exposures, or capital structure. Real-time updates from EDGAR mean that new Indivior filings, including any future proxy statements on executive compensation and Form 4 insider transaction reports, are surfaced promptly.
By using this page, investors, analysts, and other stakeholders can efficiently navigate Indivior’s SEC reporting history, monitor developments in its OUD pharmaceutical business, and interpret the financial and governance implications of its regulatory disclosures.
Q2 2025 snapshot: Net revenue rose 1% YoY to $302 m as SUBLOCADE sales grew 9% to $209 m, offsetting softer U.S. sublingual products. Gross margin expanded to 83% (74% last year) after prior-year PERSERIS exit costs rolled off. Operating income swung to $72 m from a $(118) m loss and diluted EPS reached $0.14 versus $(0.72). For the first half, revenue slipped 3% to $568 m but EPS improved to $0.52.
Cash & leverage: Operating cash flow jumped to $233 m, aided by delayed rebate payments, taking cash to $510 m and creating net cash of roughly $184 m against $326 m total debt. Capital-expenditure guidance remains $50-70 m for FY25, mainly for SUBLOCADE capacity.
Legal & tax items: Antitrust liabilities are down to an NPV of $20 m, and a $79 m provision covers opioid-MDL settlement offers. New dental-injury MDL (≈21,000 plaintiffs) and U.K. shareholder suits introduce fresh uncertainty. A £33 m HMRC reserve pushed the effective tax rate to 71%.
Strategic moves: LSE delisting completed; the company joins the Russell 2000/3000 and will lose foreign-private-issuer status in 2026. Manufacturing footprint is being consolidated; a Curia supply contract ends January 2026 without material penalties.
Management outlook: Guidance implies gross margin in the low-to-mid-80% range, SG&A/R&D below 2024, and continued double-digit SUBLOCADE growth sufficient to offset mature-product erosion. Management does not expect material impact from new U.S. tax legislation.
Indivior announced two significant board-related developments in this 8-K filing. Stuart A. (Tony) Kingsley has been appointed as a non-executive director effective July 1, 2025. His appointment aligns with the Amended and Restated Relationship Agreement with Oaktree Value Opportunities Fund and related entities.
The company also disclosed new director equity arrangements:
- Five U.S.-based non-executive directors (Keith Humphreys, Daniel Ninivaggi, Barbara Ryan, Mark Stejbach, and David Wheadon) entered into a Purchase Plan with J.P. Morgan Securities for quarterly stock purchases
- The plan allows directors to defer approximately 70-80% of their after-tax base retainer into company shares
- U.K.-based director Juliet Thompson and related party Timothy Thompson purchased 1,925 and 3,850 Ordinary Shares respectively, with company reimbursement planned over the next year
These arrangements demonstrate a strategic move to increase share ownership among non-executive directors, aligning with the 2025 Directors' Remuneration Policy approved by shareholders.